AbbVie Inc
ABBV226.710USD
+3.890+1.75%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
400.68BMarket Cap
170.81P/E TTM
More Details of AbbVie Inc Company
AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.
AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.
The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'
AbbVie Inc Info
Ticker SymbolABBV
Company nameAbbVie Inc
IPO dateJan 02, 2013
CEOMichael (Robert A)
Number of employees55000
Security typeOrdinary Share
Fiscal year-endJan 02
Address1 N Waukegan Rd
CityNORTH CHICAGO
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code60064
Phone18479327900
Websitehttps://www.abbvie.com/
Ticker SymbolABBV
IPO dateJan 02, 2013
CEOMichael (Robert A)
Company Executives of AbbVie Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.33%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.87%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-77.61%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+91.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
4.42B
28.20%
Immunology-RINVOQ
2.03B
12.93%
Immunology-HUMIRA
1.18B
7.52%
Hematologic Oncology-IMBRUVICA
965.00M
6.15%
Neuroscience-Botox Therapeutic
928.00M
5.92%
Other
6.16B
39.27%
By RegionUSD
Name
Revenue
Proportion
United States
11.34B
72.31%
International
3.48B
22.18%
All other countries
603.00M
3.84%
Collaboration revenue
260.00M
1.66%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
4.42B
28.20%
Immunology-RINVOQ
2.03B
12.93%
Immunology-HUMIRA
1.18B
7.52%
Hematologic Oncology-IMBRUVICA
965.00M
6.15%
Neuroscience-Botox Therapeutic
928.00M
5.92%
Other
6.16B
39.27%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.25%
State Street Investment Management (US)
4.52%
Geode Capital Management, L.L.C.
2.29%
JP Morgan Asset Management
2.06%
Other
75.87%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.25%
State Street Investment Management (US)
4.52%
Geode Capital Management, L.L.C.
2.29%
JP Morgan Asset Management
2.06%
Other
75.87%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.73%
Investment Advisor/Hedge Fund
20.55%
Research Firm
3.07%
Bank and Trust
2.37%
Pension Fund
2.27%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.92%
Insurance Company
0.70%
Family Office
0.20%
Other
24.78%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
5311
1.33B
74.86%
+1.37M
2025Q3
5386
1.32B
74.95%
+8.86M
2025Q2
5326
1.32B
74.78%
+2.41M
2025Q1
5334
1.32B
74.15%
+3.84M
2024Q4
5267
1.31B
73.92%
+9.35M
2024Q3
4970
1.30B
74.13%
-1.24M
2024Q2
4907
1.30B
73.33%
+14.47M
2024Q1
4916
1.28B
72.48%
+1.37M
2023Q4
4861
1.27B
72.12%
+10.24M
2023Q3
4666
1.27B
72.28%
+8.75M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
176.50M
9.99%
+3.35M
+1.94%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
92.10M
5.21%
+1.07M
+1.18%
Jun 30, 2025
State Street Investment Management (US)
80.02M
4.53%
+61.16K
+0.08%
Jun 30, 2025
Geode Capital Management, L.L.C.
39.18M
2.22%
+924.76K
+2.42%
Jun 30, 2025
JP Morgan Asset Management
37.47M
2.12%
+1.87M
+5.24%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
26.78M
1.52%
+1.52M
+6.01%
Jun 30, 2025
Capital Research Global Investors
25.27M
1.43%
-8.24M
-24.60%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
23.51M
1.33%
+254.93K
+1.10%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
23.10M
1.31%
-1.99M
-7.94%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.65M
1.11%
-1.78M
-8.30%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
9.64%
First Trust NASDAQ Pharmaceuticals ETF
8.05%
Health Care Select Sector SPDR Fund
7.89%
Proshares Ultra Health Care
7.62%
iShares U.S. Healthcare ETF
7.57%
JPMorgan Healthcare Leaders ETF
6.87%
Simplify Health Care ETF
6.73%
Fidelity MSCI Health Care Index ETF
6.5%
Harbor Health Care ETF
6.18%
iShares Core High Dividend ETF
5.9%
View more
VanEck Pharmaceutical ETF
Proportion9.64%
First Trust NASDAQ Pharmaceuticals ETF
Proportion8.05%
Health Care Select Sector SPDR Fund
Proportion7.89%
Proshares Ultra Health Care
Proportion7.62%
iShares U.S. Healthcare ETF
Proportion7.57%
JPMorgan Healthcare Leaders ETF
Proportion6.87%
Simplify Health Care ETF
Proportion6.73%
Fidelity MSCI Health Care Index ETF
Proportion6.5%
Harbor Health Care ETF
Proportion6.18%
iShares Core High Dividend ETF
Proportion5.9%
Dividend
A total of
48.58B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 31, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option
Jan 16, 2026
Feb 17, 2026
Jan 16, 2026
Sep 05, 2025
ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 14, 2025
Oct 15, 2025
Jun 20, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 13, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of AbbVie Inc?
The top five shareholders of AbbVie Inc are:
The Vanguard Group, Inc. holds 176.50M shares, accounting for 9.99% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 92.10M shares, accounting for 5.21% of the total shares.
State Street Investment Management (US) holds 80.02M shares, accounting for 4.53% of the total shares.
Geode Capital Management, L.L.C. holds 39.18M shares, accounting for 2.22% of the total shares.
JP Morgan Asset Management holds 37.47M shares, accounting for 2.12% of the total shares.
The Vanguard Group, Inc. holds 176.50M shares, accounting for 9.99% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 92.10M shares, accounting for 5.21% of the total shares.
State Street Investment Management (US) holds 80.02M shares, accounting for 4.53% of the total shares.
Geode Capital Management, L.L.C. holds 39.18M shares, accounting for 2.22% of the total shares.
JP Morgan Asset Management holds 37.47M shares, accounting for 2.12% of the total shares.
What are the top three shareholder types of AbbVie Inc?
The top three shareholder types of AbbVie Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of AbbVie Inc (ABBV)?
As of 2025Q4, 5311 institutions hold shares of AbbVie Inc, with a combined market value of approximately 1.33B, accounting for 74.86% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.10%.
What is the biggest source of revenue for AbbVie Inc?
In FY2025Q2, the Immunology-SKYRIZI business generated the highest revenue for AbbVie Inc, amounting to 4.42B and accounting for 28.20% of total revenue.
